Xencor (XNCR) Non Operating Investment Income (2015 - 2026)
Xencor (XNCR) posted quarterly Non Operating Investment Income of -$51.9 million for Q1 2026, down 5618.49% year-over-year from $941000.0 in Q1 2025, and down 201.02% quarter-over-quarter from $51.4 million in Q4 2025.
Xencor (XNCR) Non Operating Investment Income (2015 - 2026) Analysis & Trends
Xencor (XNCR) has reported Non Operating Investment Income for 12 consecutive years, with -$51.9 million the latest figure, recorded in Q1 2026.
- In Q1 2026, Non Operating Investment Income fell 5618.49% year-over-year to -$51.9 million; the TTM figure through Mar 2026 stood at $48.6 million (up 248.28% YoY), while the FY2025 annual figure was $101.5 million, up 423.07% from the prior year.
- Non Operating Investment Income fell to -$51.9 million in Q1 2026 per XNCR's latest filing, from $51.4 million in the prior quarter.
- Across five years, Non Operating Investment Income topped out at $51.4 million in Q4 2025 and bottomed at -$51.9 million in Q1 2026.
- Historically, Non Operating Investment Income has averaged $3.8 million across 5 years, with a median of $2.3 million in 2024.
- Annual changes were most pronounced in 2022 — Non Operating Investment Income slumped 15008.7% — and 2024, when it jumped 671.17%.
- Xencor's Non Operating Investment Income stood at $31.8 million in 2022, then sank by 58.37% to $13.2 million in 2023, then slumped by 333.98% to -$31.0 million in 2024, then jumped by 265.96% to $51.4 million in 2025, then sank by 201.02% to -$51.9 million in 2026.
- Business Quant data shows XNCR's Non Operating Investment Income at -$51.9 million in Q1 2026, $51.4 million in Q4 2025, and $44.2 million in Q3 2025.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Non Operating Investment Income (Qtr) |
|---|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 128.13 Bn | 120.28 Bn | 2.84 Bn | - |
| 2 | Regeneron Pharmaceuticals | 112.33 Bn | 104.33 Bn | 3.93 Bn | - |
| 3 | Argenx Se | 53.24 Bn | 48.05 Bn | 1.41 Bn | - |
| 4 | Revolution Medicines | 43.64 Bn | 43.64 Bn | - | - |
| 5 | BeOne Medicines | 39.27 Bn | 34.17 Bn | 1.53 Bn | - |
| 6 | MindWalk Holdings | 35.32 Bn | 35.31 Bn | 1.82 Bn | - |
| 7 | Royalty Pharma | 33.72 Bn | 35.84 Bn | - | - |
| 8 | Alnylam Pharmaceuticals | 30.58 Bn | 27.27 Bn | 992.69 Mn | - |
| 9 | Insmed | 27.01 Bn | 25.85 Bn | 358.27 Mn | - |
| 10 | Xencor | 1.73 Bn | 1.36 Bn | - | 18.06 Mn |
Historic Data
Download Data| Date | Value |
|---|---|
| Jun 30, 2026 | 18.06 Mn |
| Jun 30, 2026 | 18.06 Mn |
| Mar 31, 2026 | -51.93 Mn |
| Mar 31, 2026 | -51.93 Mn |
| Dec 31, 2025 | 51.41 Mn |
| Dec 31, 2025 | 51.41 Mn |
| Sep 30, 2025 | 44.20 Mn |
| Sep 30, 2025 | 44.20 Mn |
| Jun 30, 2025 | 4.97 Mn |
| Jun 30, 2025 | 4.97 Mn |
| Mar 31, 2025 | 941,000.00 |
| Mar 31, 2025 | 941,000.00 |
| Dec 31, 2024 | -30.97 Mn |
| Dec 31, 2024 | -30.97 Mn |
| Sep 30, 2024 | 9.25 Mn |
| Sep 30, 2024 | 9.25 Mn |
| Jun 30, 2024 | -12.03 Mn |
| Jun 30, 2024 | -12.03 Mn |
| Mar 31, 2024 | 2.33 Mn |
| Mar 31, 2024 | 2.33 Mn |